Arcadia Biosciences, Inc. 8-K

What Happened

• Arcadia Biosciences, Inc. (RKDA) filed an 8-K (July 2, 2026) reporting two main items: the Board set the 2026 Annual Meeting of stockholders for September 10, 2026, and the company amended its Form 10-K/A to note that no 2025 executive incentive bonuses had been paid as of that filing and the cash bonus amount for Mr. Schaefer for 2025 was not yet determinable. The company said it will file a further Form 8-K disclosing any cash bonus paid to Mr. Schaefer and a recalculated total compensation figure once determined.

Key Details

• 2026 Annual Meeting date: September 10, 2026 (change of more than 30 days from the prior-year anniversary).
• Deadline for shareholder nominations/proposals to be timely: close of business on July 13, 2026.
• Proxy-solicitation notice for nominees other than the company's must comply with Rule 14a-19 and be received by July 13, 2026.
• Notice address for nominations/proposals: Arcadia Biosciences, Inc., 5956 Sherry Lane, 20th Floor, Dallas, Texas 75225, Attention: Corporate Secretary.

Why It Matters

• The meeting date change shifts the calendar for shareholders who want to submit proposals or nominate directors; missing the July 13, 2026 deadline can mean exclusion from the company’s proxy materials or ineligibility under the bylaws and SEC rules.
• The pending 2025 cash bonus for Mr. Schaefer means executive compensation disclosure in the company's filings is incomplete for now; investors should watch for the promised follow-up 8-K that will report the bonus amount and update total compensation figures.